MetaCap

BlossomHill Therapeutics (BLSM) vs Shattuck Labs (STTK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BlossomHill Therapeutics is the larger company by market cap ($461.2 million vs $454.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BLSM-9.31%STTK-38.65%
+73%+14%-44%
Aug 7, 20261 yearNov 20, 2026
BLSM-9.31%STTK-38.65%
+66%+11%-44%
Aug 3, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BLSM versus STTK key metrics
MetricBLSMSTTK
Share price$14.51$4.46
Market cap$461.20M$454.22M
1-day change+0.69%-1.98%
YTD return—+22.19%
1-year return—+119.70%
5-year return—-51.99%
EPS (TTM)$-10.38$-0.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.00M
Revenue growth (YoY)—-82.52%
Net income (latest FY)—$-48.81M
Operating margin—-5150.80%
Net margin—-4880.90%
52-week high$27.99$8.33
52-week low$11.02$1.93
Distance from 52-week high-48.16%-46.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+143.97%+245.29%
Average volume193.15K1.20M
Shares outstanding31.78M101.84M
Employees6940
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About BlossomHill Therapeutics

BLSM stock →

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).

Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees

About Shattuck Labs

STTK stock →

Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.

Health Care · Biotechnology: Pharmaceutical Preparations · 40 employees

BLSM vs STTK FAQ

Which is bigger, BlossomHill Therapeutics or Shattuck Labs?

BlossomHill Therapeutics (BLSM) is larger, with a market capitalization of $461.20M compared with $454.22M for Shattuck Labs (STTK).

Are BlossomHill Therapeutics and Shattuck Labs in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons